Financial Performance - XDEMVY net sales reached $118.7 million in Q3 2025[30], representing a ~147% year-over-year growth[11, 30] - Over 103,000 XDEMVY bottles were delivered to patients in Q3 2025[30] - The gross-to-net discount was 44.7% in Q3 2025[30] - The company projects XDEMVY net product sales of approximately $140-$145 million for Q4 2025[32] and a gross-to-net discount of ~43-45%[33] - Full-year 2025 XDEMVY net product sales are projected to be approximately $440-$445 million[34] Market and Commercial Expansion - An estimated 25 million Americans are living with Demodex blepharitis (DB)[16] - Approximately 9 million patients are proactively seeking treatment for DB or complementary eye conditions/diseases[16] - Over 20,000 eye care professionals (ECPs) are prescribing XDEMVY[20] - There was a 20% quarter-over-quarter (QoQ) growth in ECPs prescribing XDEMVY once per week[20], and a 30% QoQ growth in ECPs prescribing XDEMVY more than once per week[20] Pipeline Development - The company plans to initiate a Phase 2 study for TP-04 (ocular rosacea) in Q4 2025[35] and a Phase 2 study for TP-05 (Lyme Disease prevention) in 2026[14, 35] - The company is on track for potential submission of XDEMVY in Europe in 2026[14, 35] and regulatory approval in 2027[35]